Analysis of the curative efficacy in patients with chronic hepatitis B treated with entecavir

Objective To evaluate the curative efficacy in patients with chronic hepatitis (CHB) treated by entecavir(ETV).Methods 29 patients with CHB(5 HBV-chronic carriers,11 mild cases and 13 moderate cases))were treated with entecavir and detected serum HBV-DNA,ALT,AST level and HBeAg seroconversion.Results Serum HBV-DNA levels of 3 groups were dropped gradually with the therapy.The average declining counts compared with the baseline were increased too.There were no significant differences in the 3 groups compared with each other.After 24 weeks,the rates of HBV-DNA reduced to negative were 48.1%,62.5% and 99.8% in HBV-chronic carriers group,mild group and moderate group respectively.The rates of HBV-DNA reduced to negative in moderate group were higher than that of in HBV-chronic carriers group at 12,24,36 weeks(P0.05).The rate of HBV-DNA reduced to negative in moderate group was higher than that in mild group at 12 weeks only(P0.01).5 cases(38.5%) procured HBeAg seroconversion at 48 weeks in moderate group.3 cases (27.3%) procured HBeAg seroconversion at 48 weeks in moderate group.ALT/AST recovered to normal in mild group at 36 weeks,in moderate group at 24 weeks respectively.Conclusion ETV is efficacy and safety in patients with chronic hepatitis B.